PET-CT for Non-Hodgkin Lymphoma: Staging and Response Assessment
Share
Non-Hodgkin lymphoma (NHL) is one of the cancers where PET-CT has fundamentally changed care. For most FDG-avid subtypes, PET-CT is now standard at three points: initial staging, interim treatment response, and end-of-treatment response. The interpretation framework — the Lugano classification and Deauville 5-point score — is internationally consistent, so a scan done at a top center anywhere in the world reads the same way. This guide explains the framework, the timing, and the practical pathway for international patients.
NHL Subtypes and PET-CT Avidity
Not all lymphomas are FDG-avid. The 2014 Lugano classification grouped subtypes by FDG behavior:
| FDG behavior | NHL subtypes |
|---|---|
| Consistently avid (PET-stageable) | Diffuse large B-cell lymphoma (DLBCL), follicular grade 3, mantle cell, Burkitt, Hodgkin lymphoma (all subtypes) |
| Variable avidity | Follicular grade 1–2, marginal zone, lymphoplasmacytic |
| Low avidity (CT-staged) | Small lymphocytic / CLL, extranodal MZL of MALT, primary cutaneous T-cell |
For consistently avid subtypes, PET-CT is mandatory at staging. For variable subtypes, baseline PET-CT is recommended to characterize the patient's particular disease — if avid, follow with PET; if not, follow with CT.
Lugano Classification for Staging
The Lugano staging system replaces older Ann Arbor staging for FDG-avid lymphomas:
- Stage I: Single lymph node region or single extralymphatic site
- Stage II: Two or more lymph node regions on the same side of the diaphragm
- Stage III: Lymph nodes on both sides of the diaphragm
- Stage IV: Diffuse extralymphatic involvement (liver, bone marrow, lung parenchyma)
Modifiers:
- A — no B symptoms (no fever, night sweats, weight loss >10%)
- B — B symptoms present
- E — extranodal contiguous extension
- X — bulky disease (mass >10 cm or >1/3 of mediastinal width)
PET-CT provides the staging substrate; combined with bone marrow biopsy (when indicated) and CSF analysis (in high-risk DLBCL), the full stage is determined.
Deauville 5-Point Score Explained
Interim and end-of-treatment response are scored on the Deauville 5-point scale, comparing FDG uptake at the most active disease site to reference tissues:
| Score | Uptake compared to reference |
|---|---|
| 1 | No uptake above background |
| 2 | Uptake ≤ mediastinal blood pool |
| 3 | Uptake > mediastinum but ≤ liver |
| 4 | Uptake moderately > liver |
| 5 | Uptake markedly > liver and/or new lesions |
| X | New uptake unlikely related to lymphoma |
Score 1–3 is generally considered "PET-negative" (complete metabolic response). Score 4–5 is "PET-positive" (residual disease likely). Score X requires clinical correlation.
Interim PET After 2-4 Cycles
For Hodgkin lymphoma and DLBCL, interim PET-CT after 2 cycles of chemotherapy (PET-2) provides early response assessment that can guide treatment escalation or de-escalation.
Clinical interpretation:
- PET-2 Deauville 1–3: Complete metabolic response. Continue planned chemotherapy. In Hodgkin lymphoma trials, sometimes used to de-escalate (omit consolidative radiation).
- PET-2 Deauville 4: Partial response. Most patients continue standard chemotherapy with closer monitoring.
- PET-2 Deauville 5: Treatment failure. Switch to second-line regimen. Consider stem cell transplant evaluation.
Major trials (RATHL for Hodgkin, GAINED for DLBCL, AHL2011) have established the prognostic value of PET-2 — patients who achieve negative PET-2 have substantially better long-term outcomes.
End-of-Treatment Response Assessment
After completion of planned chemotherapy:
- Deauville 1–3: Complete metabolic response (CMR). Goal achieved. Move to surveillance.
- Deauville 4: Partial response. Consolidative radiation or second-line therapy depending on subtype, risk factors, and original treatment intent.
- Deauville 5: Refractory disease. Salvage therapy.
Bulky disease at presentation (any node >7.5 cm in some protocols, >10 cm in others) often gets consolidative radiotherapy to the original mass site regardless of PET response — radiation has independent benefit in reducing local recurrence.
For treatment response interpretation in NHL, our team can help.
Surveillance PET vs CT-Only Follow-Up
After complete metabolic response, routine surveillance PET-CT is generally NOT recommended for asymptomatic patients:
- Risk of false positives: 15–25% of follow-up PETs show focal uptake (often inflammation or post-treatment changes) that prompts further workup and biopsy
- Cumulative radiation: 5+ years of annual PET-CT adds 40–60 mSv
- No proven survival benefit: large studies show no survival difference between routine PET surveillance and symptom-triggered imaging
Standard surveillance for most NHL: clinical exam every 3 months for 2 years, then 6-month, then annual. Imaging (CT, occasionally PET) only if symptoms or new abnormal lab findings.
Exceptions: aggressive subtypes (PCNSL, transformed FL, Richter transformation) may warrant scheduled PET surveillance.
False Positives in NHL Workup
Common sources of FDG uptake mimicking lymphoma:
- Post-chemotherapy thymic rebound — common in young adults, can be intense
- Bone marrow activation from G-CSF or recent transfusion — diffuse marrow uptake
- Sarcoidosis — bilateral hilar/mediastinal nodes with FDG uptake; can be confused with mediastinal lymphoma
- Tuberculosis or fungal infection — focal nodal uptake
- Reactive lymph nodes from any active infection
- Vaccination site — recent COVID, flu, or other vaccine causes ipsilateral axillary uptake
- Radiation pneumonitis — within 6 months of chest radiation
- Brown adipose tissue — supraclavicular, paraspinal
A skilled hematologist-oncologist interprets PET findings in context of the patient's recent history and overall clinical picture.
Where to Get PET-CT for Lymphoma in China
Centers with strong lymphoma PET programs:
- Peking Union Medical College Hospital (PUMC), Beijing — lymphoma multidisciplinary clinic
- Ruijin Hospital, Shanghai — leading hematology center; Lugano protocol standard
- Shanghai Renji Hospital — large hematology service
- Fudan Shanghai Cancer Center — comprehensive PET program
- Sun Yat-sen Cancer Center, Guangzhou — regional hematology referral
- Tianjin Medical University Cancer Hospital — hematologic malignancy specialty
International patients typically arrive after pathology confirmation (often with slides for confirmatory review). The pathway:
- Send pathology, prior imaging, treatment history
- Pre-arrival video consult with hematology
- Day 1: hematology consultation, lab work, image review
- Day 2: PET-CT
- Day 3: results and treatment plan
- Subsequent: treatment delivered locally or back home
Cost: ¥6,500–9,500 per PET-CT; full staging workup with hematology consult, baseline labs, and PET typically ¥12,000–20,000.
Frequently Asked Questions
Why does my report use "Deauville 3" rather than "complete response"?
Deauville 3 is in a gray zone. Most clinicians treat it as complete metabolic response, but some treat as partial — particularly in interim PET. The decision depends on subtype, risk factors, and clinical trial context.
Is interim PET necessary in every NHL?
For DLBCL and Hodgkin lymphoma in major trials, yes. For other subtypes, the data are less robust. Some oncologists do interim PET routinely; others reserve it for cases where the result might change treatment.
Will Rituximab affect the PET interpretation?
Rituximab (anti-CD20) is widely used in B-cell NHL. It does not directly cause false-positive PET findings. Treatment effects appear as expected reduction in tumor uptake.
Can I have PET if I just had a recent chemotherapy cycle?
Yes, but timing matters. Some protocols wait 3 weeks post-chemotherapy to allow temporary inflammation to subside. Discuss timing with the imaging team.
Does PET change the management of indolent lymphomas?
For follicular grade 1–2, marginal zone, and small lymphocytic lymphomas, PET is less central. CT and clinical assessment remain primary. Baseline PET to characterize FDG avidity is recommended.
Can my home oncologist work with reports from China?
Yes. Lugano and Deauville are international standards. A Chinese PET-CT report (translated into English) reads the same as a US or UK report. The image disc is universally compatible.
Need Help Booking?
SinoCareLink can pre-book PET-CT at a top Chinese cancer center with lymphoma expertise, arrange teleradiology second-opinion reads, coordinate hematology consults, translate reports, and arrange airport pickup. Contact us for a free consultation.